(NASDAQ:SILO) SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University.
Related Questions
What impact will the Australian patent grant have on Silo Pharma’s expected timeline and revenue forecasts for the PTSD drug candidate?
How might this expanded IP portfolio influence market perception, partnership opportunities, and valuation relative to peers?
Will the new patent affect the company’s upcoming financing plans or potential M&A activity, and how should we position our trades accordingly?